Arrowhead Pharmaceuticals, Inc.
ARWR
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial toā¦ read more
Healthcare
Biotechnology
32 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$77.55
Price-1.89%
-$1.49
1Y
Price
Market Cap
$10.923b
Large
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-191.6%
EBITDA Margin-180.0%
Net Profit Margin+111.0%
Free Cash Flow Margin-191.6%
EBITDA Margin-180.0%
Net Profit Margin+111.0%
Free Cash Flow MarginRevenue
$622.009m
-25.0%
1y CAGR+7711.5%
3y CAGR+5783.4%
5y CAGREarnings
-$300.912m
-18349.5%
1y CAGR-6147.3%
3y CAGR-4614.6%
5y CAGREPS
-$2.14
-21300.0%
1y CAGR-7120.2%
3y CAGR-5343.9%
5y CAGRBook Value
$598.916m
$2.268b
Assets$1.669b
Liabilities$1.373b
DebtDebt to Assets
60.5%
-8.2x
Debt to EBITDAFree Cash Flow
-$50.872m
-132.4%
1y CAGR-29.7%
3y CAGR-41.1%
5y CAGRNo items found.
Press Releases
Statements and updates from the company